DK1718967T3 - Metoder til at detektere Lp-PLA2 aktivitet - Google Patents
Metoder til at detektere Lp-PLA2 aktivitetInfo
- Publication number
- DK1718967T3 DK1718967T3 DK05712595.7T DK05712595T DK1718967T3 DK 1718967 T3 DK1718967 T3 DK 1718967T3 DK 05712595 T DK05712595 T DK 05712595T DK 1718967 T3 DK1718967 T3 DK 1718967T3
- Authority
- DK
- Denmark
- Prior art keywords
- detecting
- methods
- pla2 activity
- pla2
- activity
- Prior art date
Links
- 102000016752 1-Alkyl-2-acetylglycerophosphocholine Esterase Human genes 0.000 title 1
- 108010024976 Asparaginase Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
- C12Q1/44—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving esterase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/08—1,2,5-Oxadiazoles; Hydrogenated 1,2,5-oxadiazoles
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
- G01N2333/918—Carboxylic ester hydrolases (3.1.1)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Rheumatology (AREA)
- Virology (AREA)
- Biotechnology (AREA)
- Urology & Nephrology (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Communicable Diseases (AREA)
- Surgery (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US54158304P | 2004-02-03 | 2004-02-03 | |
| PCT/US2005/003211 WO2005074604A2 (en) | 2004-02-03 | 2005-02-03 | METHODS OF DETECTING Lp-PLA2 ACTIVITY |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1718967T3 true DK1718967T3 (da) | 2013-06-03 |
Family
ID=34837507
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK05712595.7T DK1718967T3 (da) | 2004-02-03 | 2005-02-03 | Metoder til at detektere Lp-PLA2 aktivitet |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20070281323A1 (da) |
| EP (2) | EP2280282A1 (da) |
| JP (2) | JP5155564B2 (da) |
| DK (1) | DK1718967T3 (da) |
| ES (1) | ES2416344T3 (da) |
| WO (1) | WO2005074604A2 (da) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE602004026439D1 (de) | 2003-05-28 | 2010-05-20 | Glaxo Group Ltd | Lp-pla2-aktivitätstest mit hohem durchsatz |
| US20070166777A1 (en) * | 2004-04-16 | 2007-07-19 | Yaping Shou | Methods for detecting lp-pla2 activity and inhibition of lp-pla2 activity |
| US20150017671A1 (en) | 2004-04-16 | 2015-01-15 | Yaping Shou | Methods for detecting lp-pla2 activity and inhibition of lp-pla2 activity |
| EP2313778B1 (en) * | 2008-07-18 | 2015-01-28 | Boston Medical Center Corporation | Diagnostics for membranous nephropathy |
| EP2246440A1 (en) * | 2009-04-29 | 2010-11-03 | Aterovax | Enzymatic assay for the quantitative determination of phospholipase a1 or a2 activity in a sample |
| WO2012003475A1 (en) * | 2010-07-02 | 2012-01-05 | Bg Medicine, Inc. | Statin therapy monitored by galectin- 3 measurement |
| CN102692507B (zh) * | 2011-07-29 | 2015-09-16 | 南京诺尔曼生物技术有限公司 | 脂蛋白相关磷脂酶a2(lppla2)测定试剂盒(胶乳增强免疫比浊法) |
| CN103048457B (zh) * | 2012-11-27 | 2014-12-17 | 同昕生物技术(北京)有限公司 | 心肌梗死预警胶体金试剂盒及其制备方法 |
| US20140283157A1 (en) * | 2013-03-15 | 2014-09-18 | Diadexus, Inc. | Lipoprotein-associated phospholipase a2 antibody compositions and methods of use |
| CN104237517B (zh) * | 2013-06-18 | 2016-05-18 | 深圳市安群生物工程有限公司 | 检测人Lp-PLA2蛋白的荧光免疫层析试纸及其制备方法 |
| US20150086998A1 (en) * | 2013-09-24 | 2015-03-26 | Thomas D. Schaal | Value-assigned solutions of lipoprotein-associated phospholipase a2 having a long shelf-life |
| CN103792353B (zh) * | 2013-10-17 | 2015-07-15 | 武汉生之源生物科技有限公司 | 一种脂蛋白相关磷脂酶a2含量检测试剂盒及其制备方法 |
| WO2015058158A1 (en) * | 2013-10-18 | 2015-04-23 | Diadexus, Inc. | METHOD FOR DETECTION OF LIPOPROTEIN-SPECIFIC Lp-PLA2 ASSOCIATION |
| CN104634970B (zh) * | 2015-02-10 | 2017-04-05 | 深圳市新产业生物医学工程股份有限公司 | 用于检测脂蛋白相关磷脂酶a2的试剂盒及其制备和应用 |
| WO2016127319A1 (zh) | 2015-02-10 | 2016-08-18 | 深圳市新产业生物医学工程股份有限公司 | 用于检测脂蛋白相关磷脂酶a2的试剂盒及其制备和应用 |
| CN104820097A (zh) * | 2015-05-22 | 2015-08-05 | 北京协和洛克生物技术有限责任公司 | 一种定量检测样本中脂蛋白磷脂酶a2浓度的液态芯片试剂盒及其制备方法 |
| US11237167B2 (en) * | 2017-01-24 | 2022-02-01 | Cleveland Heartlab, Inc. | Lp-PLA2 assays and composition with detergent |
| CN109917131B (zh) * | 2019-03-26 | 2021-12-17 | 苏州博源医疗科技有限公司 | 一种脂蛋白磷脂酶a2检测试剂及其制备和使用方法 |
| CN111175242A (zh) * | 2020-03-17 | 2020-05-19 | 湖南新大陆生物技术有限公司 | 一种脂蛋白磷脂酶a2检测试剂盒及其应用 |
| CN111662387A (zh) * | 2020-07-14 | 2020-09-15 | 重庆中元汇吉生物技术有限公司 | 抗人脂蛋白相关磷脂酶a2单克隆抗体及其应用 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| US4925788A (en) | 1986-10-24 | 1990-05-15 | Immunicon Corporation | Immunoassay system and procedure based on precipitin-like interaction between immune complex and Clq or other non-immunospecific factor |
| US5108933A (en) | 1988-09-16 | 1992-04-28 | Immunicon Corporation | Manipulation of colloids for facilitating magnetic separations |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| WO1992002551A1 (en) | 1990-08-02 | 1992-02-20 | B.R. Centre Limited | Methods for the production of proteins with a desired function |
| US5200084A (en) | 1990-09-26 | 1993-04-06 | Immunicon Corporation | Apparatus and methods for magnetic separation |
| US5186827A (en) | 1991-03-25 | 1993-02-16 | Immunicon Corporation | Apparatus for magnetic separation featuring external magnetic means |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| US5869619A (en) | 1991-12-13 | 1999-02-09 | Xoma Corporation | Modified antibody variable domains |
| DE69233204T2 (de) | 1991-12-13 | 2004-07-15 | Xoma Corp., Berkeley | Verfahren und materialien zur herstellung von modifizierten variablen antikörperdomänen und ihre therapeutische verwendung |
| EP0590327B1 (en) | 1992-09-11 | 2003-04-09 | F. Hoffmann-La Roche Ag | Detection of nucleic acids in blood |
| AU670108B2 (en) * | 1992-09-11 | 1996-07-04 | Becton Dickinson & Company | Improved antibodies to plasmodium falciparum |
| US6180377B1 (en) | 1993-06-16 | 2001-01-30 | Celltech Therapeutics Limited | Humanized antibodies |
| US5981252A (en) | 1993-06-25 | 1999-11-09 | Smithkline Beecham | Lipoprotein associated phospholipase A2, inhibitors thereof and use of the same in diagnosis and therapy |
| US5977308A (en) | 1993-10-06 | 1999-11-02 | Icos Corporation | Platelet-activating factor acetylhydrolase |
| DE69434609T2 (de) | 1993-10-06 | 2006-09-21 | Icos Corp., Bothell | Acethylhydrolase des Plättchen aktivierenden Faktors |
| US5847088A (en) | 1993-10-06 | 1998-12-08 | Icos Corporation | Antibodies specific for platelet-activating factor acetylhydrolase |
| US5656431A (en) | 1993-10-06 | 1997-08-12 | Icos Corporation | Platelet-activating factor acetylhydrolase |
| US6156504A (en) | 1996-03-15 | 2000-12-05 | The Penn State Research Foundation | Detection of extracellular tumor-associated nucleic acid in blood plasma or serum using nucleic acid amplification assays |
| US6630301B1 (en) | 1997-03-14 | 2003-10-07 | The Penn State Research Foundation | Detection of extracellular tumor-associated nucleic acid in blood plasma or serum |
| US6013256A (en) | 1996-09-24 | 2000-01-11 | Protein Design Labs, Inc. | Method of preventing acute rejection following solid organ transplantation |
| EP1057024A4 (en) * | 1998-02-23 | 2002-10-30 | Diadexus Inc | METHOD FOR USING PLA 2? AS A METASTASE MARKER AND ASU-SELECTED CARCINOMAS FOR DIAGNOSIS |
| WO2000024910A1 (en) | 1998-10-28 | 2000-05-04 | Smithkline Beecham Plc | Process of purification of low density lipoprotein associated phospholipase a2 using immobilized metal affinity chromatography |
| EP1133523A1 (en) | 1998-11-16 | 2001-09-19 | Genway Biotech, Inc. | Generation of antibodies using polynucleotide vaccination in avian species |
| JP4220603B2 (ja) | 1998-12-02 | 2009-02-04 | アルフレッサファーマ株式会社 | 血小板活性化因子アセチルヒドロラーゼ活性の測定方法 |
| WO2000047998A1 (en) | 1999-02-10 | 2000-08-17 | Cell Works Inc. | Class characterization of circulating cancer cells isolated from body fluids and methods of use |
| JP2002051164A (ja) * | 2000-05-24 | 2002-02-15 | Victor Co Of Japan Ltd | 音声コンテンツ試聴システム及びシステムサーバ並びに携帯電話機 |
| DE50102625D1 (de) | 2001-12-07 | 2004-07-22 | Sirs Lab Gmbh | Verbindungen zur Bestimmung der Aktivität von Phospholipase A2 |
| DE602004026439D1 (de) | 2003-05-28 | 2010-05-20 | Glaxo Group Ltd | Lp-pla2-aktivitätstest mit hohem durchsatz |
-
2005
- 2005-02-03 DK DK05712595.7T patent/DK1718967T3/da active
- 2005-02-03 JP JP2006552204A patent/JP5155564B2/ja not_active Expired - Fee Related
- 2005-02-03 EP EP10185947A patent/EP2280282A1/en not_active Withdrawn
- 2005-02-03 ES ES05712595T patent/ES2416344T3/es not_active Expired - Lifetime
- 2005-02-03 US US10/588,339 patent/US20070281323A1/en not_active Abandoned
- 2005-02-03 EP EP05712595.7A patent/EP1718967B1/en not_active Expired - Lifetime
- 2005-02-03 WO PCT/US2005/003211 patent/WO2005074604A2/en not_active Ceased
-
2011
- 2011-04-05 JP JP2011083991A patent/JP2011177182A/ja not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| EP2280282A1 (en) | 2011-02-02 |
| EP1718967B1 (en) | 2013-04-24 |
| JP2007523644A (ja) | 2007-08-23 |
| JP5155564B2 (ja) | 2013-03-06 |
| EP1718967A4 (en) | 2008-03-05 |
| ES2416344T3 (es) | 2013-07-31 |
| JP2011177182A (ja) | 2011-09-15 |
| US20070281323A1 (en) | 2007-12-06 |
| WO2005074604A3 (en) | 2005-12-29 |
| WO2005074604A2 (en) | 2005-08-18 |
| EP1718967A2 (en) | 2006-11-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1718967T3 (da) | Metoder til at detektere Lp-PLA2 aktivitet | |
| DE602005022454D1 (de) | Enzymatische nachweistechniken | |
| ATE446090T1 (de) | Thiadiazolidinone als gsk3-inhibitoren | |
| DE602005024280D1 (de) | Objektdetektor | |
| CY2016009I2 (el) | Ενωσεις για την αναστολη του ενζυμου πρωτεασωματος | |
| EP1736763A4 (en) | ANALISEUR | |
| DE602005003147D1 (de) | Messsystem | |
| PL2387014T3 (pl) | System do wykrywania wielu zagrożeń | |
| EP1751652A4 (en) | MONITOR DEVICE | |
| DK1598097T3 (da) | Byggesystem | |
| EP1747756A4 (en) | Lancet assembly | |
| DK2433943T3 (da) | Mellemprodukter til thienopyrazol-derivater med PDE7-inhibitorisk aktivitet | |
| ATE400271T1 (de) | Aryl-pyridinderivate als 11-beta-hsd1-hemmer | |
| EP1752407A4 (en) | LIFT SYSTEM | |
| NO20042409D0 (no) | System and method for presence detection | |
| ATE420076T1 (de) | Indozolonderivate als 11b-hsd1-inhibitoren | |
| EP1795898A4 (en) | ANALYSIS DEVICE | |
| DE602005020180D1 (de) | Verbessertes messsystem | |
| DE602004031602D1 (de) | Vorverstärker | |
| DE502005000300D1 (de) | Tastkopf | |
| FI20040165L (fi) | Järjestelmä kunnonvalvontaa varten | |
| FI20045242A0 (fi) | Tiedon arviointi | |
| FI20050681A0 (fi) | Paikoitusmenetelmä | |
| SE0500634L (sv) | Övervakningssystem | |
| EP1832992A4 (en) | GENOME ANALYSIS METHOD |